Critical Care Anxiety and Long-Term Outcomes Management
CALM
1 other identifier
interventional
10
0 countries
N/A
Brief Summary
The aims of this study are to (1) test the benefits of a non-pharmacologic anxiety management approach with patients who are critically ill and/or traumatically injured during intensive care hospitalization and (2) test whether this approach reduces anxiety and improves engagement in rehabilitation therapies, shortens duration of hospitalization, and improves psychological and quality of life outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2 anxiety
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 10, 2015
CompletedFirst Posted
Study publicly available on registry
April 21, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2016
CompletedNovember 1, 2016
October 1, 2016
10 months
April 10, 2015
October 28, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Anxiety (Visual Analog Scale for Anxiety (VAS-A)
Anxiety at discharge and change in anxiety from baseline to discharge as measured by the Visual Analog Scale for Anxiety (VAS-A)
Participants will be followed for the duration of hospitalization, an expected average of 13 days and not more than 45 days
Secondary Outcomes (5)
Engagement in rehabilitation therapies (As measured by a 2-item engagement questionnaire)
As measured by a 2-item engagement questionnaire (developed specifically for this study) at the time of hospital discharge (i.e., based on an expected average duration of hospitalization of 13 days and not more than 45 days)
Length of ICU and Hospital Stay
Measured in days (an expected average ICU stay=5 days and average Hospital stay=13 days and not more than 45 days)
Long-Term Anxiety and Depressive Symptoms (as measured by the Hospital Anxiety and Depression Scale (HADS)
3 months after enrollment as measured by the Hospital Anxiety and Depression Scale (HADS)
Long-Term Posttraumatic Stress Symptoms (as measured by the PCL-5)
3 months after enrollment as measured by the PCL-5
Health-Related Quality of Life (as measured by the EQ-5D-5L and SF-36)
3 months after enrollment
Study Arms (2)
Anxiety Management (AM)
EXPERIMENTALUsual Care (UC)
PLACEBO COMPARATORInterventions
The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and "optional" modules based on each participant's anxiety experience and preference.
The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C\&L service; (2) referral to psychiatry C\&L service; or (3) pharmacologic management.
Eligibility Criteria
You may qualify if:
- years or older
- Ability to read, write, and speak English
- Alert (Best RASS ICU sedation score ≥-2)
- Current CAM-ICU test negative
- Expected ICU stay ≥48 hours
- Anxiety Visual Analog Scale (VAS-A) score ≥30
- Prescribed rehabilitation therapy at eligibility
You may not qualify if:
- Inability to communicate (verbally, or via hand writing/gestures)
- Greater than 90% probability of mortality in hospital
- Anticipated discharge to hospice or transition to end-of-life care
- Pre-existing cognitive impairment (e.g., dementia, pervasive developmental disorder)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
April 10, 2015
First Posted
April 21, 2015
Study Start
April 1, 2015
Primary Completion
February 1, 2016
Last Updated
November 1, 2016
Record last verified: 2016-10